SJG-136

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C31H32N4O6
Molecular Weight	556.609
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H][C@@]12CC(=C)CN1C(=O)C3=C(C=C(OCCCOC4=CC5=C(C=C4OC)C(=O)N6CC(=C)C[C@@]6([H])C=N5)C(OC)=C3)N=C2

InChI

InChIKey=RWZVMMQNDHPRQD-SFTDATJTSA-N

InChI=1S/C31H32N4O6/c1-18-8-20-14-32-24-12-28(26(38-3)10-22(24)30(36)34(20)16-18)40-6-5-7-41-29-13-25-23(11-27(29)39-4)31(37)35-17-19(2)9-21(35)15-33-25/h10-15,20-21H,1-2,5-9,16-17H2,3-4H3/t20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C31H32N4O6
Molecular Weight	556.609
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

BN-2629 (also known as SJG-136 and SG2000), a dimeric pyrrolobenzodiazepine that binds in the minor groove of DNA and produces G-G interstrand cross-links via reactive N(10)-C(11)/N(10')-C(ll') imine/carbinolamine moieties. This drug was investigated in phase II clinical trials in patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer, however, these studied were terminated because of the slow accrual. In addition, BN-2629 participated in phase I/II trial in participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia, but Spirogen also terminated these studies.

Originator

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278	Crosslinking Agent 81

PubMed

PubMed

Show entries

Title	Date	PubMed
Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.	2001 Mar 1	11262084

Showing 1 to 1 of 1 entries

Previous1Next

Sample Use Guides

In Vivo Use Guide

Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia: 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).

Route of Administration: Intravenous

Substance Class	Chemical
Record UNII	KT0ZQ64X1A
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

SJG-136

Common Name

English

BN-2629

Code

English

SP-2001

Code

English

SJG 136 [WHO-DD]

Common Name

English

NSC-694501

Code

English

Showing 1 to 5 of 9 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DB11965

PRIMARY

FDA UNII

KT0ZQ64X1A

PRIMARY

WEB RESOURCE

SJG-136

PRIMARY

CAS

232931-57-6

PRIMARY

NCI_THESAURUS

C29435

PRIMARY

Showing 1 to 5 of 9 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					KT0ZQ64X1A

SJG-136

ACTIVE MOIETY

Comments:

Company: AstraZeneca plc, Description: Small molecule pyrrolobenzodiazepine dimer that forms DNA crosslinks, Molecular Target: DNA, Mechanism of Action: Breaks/crosslinks DNA, Therapeutic Modality: Small molecule


					KT0ZQ64X1A

SJG-136

ACTIVE MOIETY

Comments:

SJG-136 (NSC 694501) is a rationally designed pyrrolobenzodiazepine dimer that binds in the minor groove of DNA. Sensitive cell lines exhibit total growth inhibition and 50% lethality after treatment with as little as 0.83 and 7.1 nmol/L SJG-136, respectively.

Showing 1 to 2 of 2 entries

Previous1Next